This Article Free upon publication Full Text Full Text (PDF) Data Supplement All Versions of this Article: 51/4/1103    most recent HYPERTENSIONAHA.107.105296v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Os, I. Articles by Oparil, S. Search for Related Content PubMed PubMed Citation Articles by Os, I. Articles by Oparil, S. Related Collections Hypertrophy Clinical Studies

(Hypertension. 2008;51:1103.)
© 2008 American Heart Association, Inc.

Go Red Original Articles

Effects of Losartan in Women With Hypertension and Left Ventricular Hypertrophy

Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study

Ingrid Os; Veronica Franco; Sverre E. Kjeldsen; Karin Manhem; Richard B. Devereux; Eva Gerdts; Darcy A. Hille; Paulette A. Lyle; Peter M. Okin; Björn Dahlöf; Suzanne Oparil

From the Department of Nephrology (I.O., S.E.K.), Ullevaal University Hospital, Oslo, Norway; University of Oslo (I.O.), Oslo, Norway; Ohio State University (V.F.), Columbus; University of Alabama at Birmingham (S.O.); University of Michigan (S.E.K.), Ann Arbor; Sahlgrenska University Hospital/Östra (K.M., B.D.), Gothenburg, Sweden; Weill Cornell Medical College (R.B.D., P.M.O.), New York, NY; Institute of Medicine (E.G.), University of Bergen, Bergen, Norway; Department of Heart Disease (E.G.), Haukeland University Hospital, Bergen, Norway; and Merck Research Laboratories (D.A.H., P.A.L.), Upper Gwynedd, Pa.

Correspondence to Ingrid Os, Department of Nephrology, Ullevaal University Hospital, 0407 Oslo, Norway. E-mail ingrid.os{at}medisin.uio.no

Hypertension is a risk factor for cardiovascular disease and outcomes in women. These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women. Fewer events occurred in women versus men. Women in the losartan group had significant reductions in the primary end point (215 [18.2 per 1000 patient-years] versus 261 [22.5 per 1000 patient-years]; hazard ratio [HR]: 0.82 [95% CI: 0.68 to 0.98]; P=0.031), stroke (109 versus 154; HR: 0.71 [95% CI: 0.55 to 0.90]; P=0.005), total mortality (HR: 0.77 [95% CI: 0.63 to 0.95]; P=0.014), and new-onset diabetes (HR: 0.75 [95% CI: 0.59 to 0.94]; P=0.015) versus the atenolol group, with no between-treatment difference for myocardial infarction (HR: 1.02 [95% CI: 0.74 to 1.39]; P=0.925), cardiovascular mortality (HR: 0.86 [95% CI: 0.64 to 1.14]; P=0.282), or hospitalization for heart failure (HR: 0.94 [95% CI: 0.68 to 1.28]; P=0.677). More women in the losartan group required hospitalization for angina (HR: 1.70 [95% CI: 1.16 to 2.51]; P=0.007). Risk reductions for the primary composite end point, stroke, total mortality, and new-onset diabetes were significantly greater with losartan- versus atenolol-based treatment in women with hypertension and left ventricular hypertrophy in the LIFE study. The risk reductions for losartan, along with the tests for the interaction of treatment and gender, indicated that the treatment effect was consistent in men and women for all of the end points tested, with the exception of hospitalization for angina.

Key Words: gender • hypertension • left ventricular hypertrophy • outcomes

This article has been cited by other articles:

				D. J. Campbell Can the Study of Female Rats Help Our Understanding of Women? Hypertension, December 1, 2008; 52(6): e142 - e142. [Full Text] [PDF]

				A. K. Sampson, K. M. Moritz, E. S. Jones, R. E. Widdop, and K. M. Denton Response to Can the Study of Female Rats Help Our Understanding of Women? Hypertension, December 1, 2008; 52(6): e143 - e143. [Full Text] [PDF]

				E. Agabiti-Rosei and M. Salvetti Gender Differences in the Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy Hypertension, July 1, 2008; 52(1): 59 - 60. [Full Text] [PDF]

				C. Escobar and V. Barrios Gender Differences in Left Ventricular Hypertrophy Regression Hypertension, June 1, 2008; 51(6): e58 - e58. [Full Text] [PDF]

				I. Os, R. B. Devereux, and P. M. Okin Response to Gender Differences in Left Ventricular Hypertrophy Regression Hypertension, June 1, 2008; 51(6): e59 - e59. [Full Text] [PDF]